Jonathan N. Menachem1, Edo Y. Birati2, Payman Zamani2, Anjali T. Owens2, Pavan Atluri3, Christian A. Bermudez3, David Drajpuch2, Stephanie Fuller4, Yuli Y. Kim2, Christopher E. Mascio4, Vikram Palanivel2, J. Eduardo Rame2, Joyce Wald2, Michael A. Acker3, Jeremy A. Mazurek2
Congenital Heart Disease, Vol.13, No.4, pp. 492-498, 2018, DOI:10.1111/chd.12606
Abstract Background: Heart failure (HF) is the leading cause of death in adults with congenital heart disease
(ACHD). Identification of disease progression and timing of referral for advanced therapies is often
delayed. However, increased awareness and understanding of ACHD and improvements in the
approach to treatment have led to improved outcomes. Pulmonary hypertension (PH) is a common
barrier to HT. In ACHD, the approach to PH and HT is quite complicated, given the anatomic heterogeneity and lower prevalence and experience. However, in some cases, PH is a result of
elevated systemic filling pressures and low output.
Methods: We… More >
Login
Register
